News

GlobalData on MSN2mon
FDA expands Enhertu approval to include HER2-ultralow breast cancer patients
The approval also allows certain patients to receive Enhertu earlier in their treatment course. Previously ... generating ...
pharmaphorum2d
Surprise Enhertu rejection follows NICE process change
NICE has rejected the use of AstraZeneca and Daiichi Sankyo’s Enhertu as an NHS treatment for advanced HER2-low breast cancer, a decision that the companies have described as “devastating”.
Nasdaq13d
AstraZeneca And Daiichi Sankyo's Enhertu Approved In EU For Advanced Breast Cancer Treatment
(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) Enhertu (trastuzumab deruxtecan) has been approved in the European Union as a treatment for adults with advanced breast ...
Share Prices13d
AstraZeneca gets EU approval for cancer treatments Enhertu and Imfinzi
The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...